The NTSR1 gene (Neurotensin Receptor 1) encodes a G protein-coupled receptor (GPCR) that binds the neuropeptide neurotensin (NT) with high affinity (Kd ~ 0.1 nM). NTSR1 is a Class A rhodopsin-like GPCR that couples primarily to Gq proteins, activating phospholipase C (PLC) and leading to protein kinase C (PKC) activation, calcium mobilization, and MAPK/ERK signaling pathway activation. In the brain, NTSR1 is highly expressed in regions rich in dopaminergic neurons, where it plays a critical role in modulating dopamine signaling andMotor control[1][2].
The neurotensin system has been increasingly recognized for its involvement in neurodegenerative diseases, particularly Parkinson's disease (PD) where NTSR1 modulates dopaminergic neuron survival and function. Additionally, NTSR1 is implicated in Alzheimer's disease (AD), schizophrenia, and various cancers. The receptor represents a promising therapeutic target, with both agonists and antagonists under investigation for neurological disorders[3][4].
| Neurotensin Receptor 1 | |
|---|---|
| Gene Symbol | NTSR1 |
| Full Name | Neurotensin Receptor 1 |
| Chromosome | 2q24.1 |
| NCBI Gene ID | [4919](https://www.ncbi.nlm.nih.gov/gene/4919) |
| OMIM | 162650 |
| Ensembl ID | ENSG00000102468 |
| UniProt ID | [P21439](https://www.uniprot.org/uniprot/P21439) |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, Schizophrenia, Cancer |
The NTSR1 gene is located on chromosome 2q24.1 and spans approximately 30 kilobases. It consists of multiple exons that encode a GPCR protein of approximately 418 amino acids.
| Property | Value |
|---|---|
| Gene Symbol | NTSR1 |
| Chromosomal Location | 2q24.1 |
| NCBI Gene ID | 4919 |
| Ensembl ID | ENSG00000102468 |
| UniProt | P21439 |
| RefSeq | NM_002531 |
The NTSR1 protein contains the classic seven-transmembrane domain structure of Class A GPCRs:
Recent cryo-EM structures have revealed the detailed molecular interactions between NTSR1 and neurotensin, providing insights for rational drug design[5].
NTSR1 activation initiates multiple signaling cascades:
Gq-PLC Pathway:
MAPK/ERK Pathway:
Beyond Gq, NTSR1 can activate:
| Pathway | Mechanism | Cellular Effects |
|---|---|---|
| PI3K/AKT | Gq-dependent and β-arrestin | Cell survival |
| JNK | Gq-dependent | Stress response |
| p38 MAPK | β-arrestin | Inflammation |
| RhoA | G12/13 coupling | Cytoskeletal dynamics |
NTSR1 signaling is tightly controlled:
NTSR1 exhibits high expression in brain regions associated with motor control and reward:
NTSR1 is centrally involved in PD pathophysiology:
Dopaminergic Modulation: NTSR1 activation modulates dopamine synthesis, release, and receptor signaling. The substantia nigra has particularly high NTSR1 expression, making it a key regulator of dopaminergic neuron function[3:1][6].
Neuroprotection: NTSR1 agonists have shown neuroprotective effects in multiple models:
Mechanisms of Protection:
Therapeutic Potential: NTSR1 agonists represent disease-modifying candidates for PD. Several small molecule agonists are in development[4:2][7].
NTSR1 contributes to AD through several mechanisms:
Cholinergic Modulation: NTSR1 influences cholinergic neurotransmission, which is prominently affected in AD
Amyloid Interaction: Neurotensin levels are altered in AD brain, potentially affecting amyloid metabolism
Synaptic Dysfunction: NTSR1 signaling modulates synaptic plasticity, which is impaired in AD
Neuroinflammation: NTSR1 in microglia may contribute to neuroinflammatory processes[8]
NTSR1 has been studied in relation to schizophrenia:
Dopamine Hypothesis Link: Given the close interaction between neurotensin and dopamine systems, NTSR1 may modulate dopamine dysregulation in schizophrenia
Therapeutic Target: NTSR1 antagonists have been explored as potential antipsychotics
Genetic Associations: Some studies link NTSR1 polymorphisms with schizophrenia risk
Beyond the CNS, NTSR1 is implicated in cancer:
This represents a distinct therapeutic application outside neurodegeneration.
NTSR1 signaling promotes dopaminergic neuron survival through multiple mechanisms:
NTSR1 modulates neuroinflammatory responses:
NTSR1 modulates synaptic function in the substantia nigra:
NTSR1 agonists are being developed for PD and other disorders:
| Compound | Stage | Key Features |
|---|---|---|
| PD-149163 | Research | Brain-penetrant agonist |
| ABS-201 | Preclinical | Selective for NTSR1 |
| SB-612422 | Research | NTSR1/NTSR2 selective |
Agonist benefits in PD:
Antagonists have different therapeutic applications:
Developing NTSR1-targeted therapies faces several challenges:
No current clinical trials for NTSR1 in PD, but preclinical data support advancement:
Vincent JP, et al. Neurotensin and neurotensin receptors. Pharmacol Rev. 1995. ↩︎
St-Gelais F, et al. Neurotensin regulates dopamine and glutamate systems: implications for drug addiction. Brain Res Rev. 2004. ↩︎
Bjornstrom K, et al. Neurotensin receptor 1 in Parkinson's disease: a new therapeutic target. J Parkinsons Dis. 2018. ↩︎ ↩︎
Yang J, et al. NTSR1 agonists as disease-modifying agents in Parkinson's disease. Nat Rev Drug Discov. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Tang W, et al. Structure of human neurotensin receptor 1 in complex with neurotensin. Nature. 2022. ↩︎
Liu L, et al. Neurotensin and dopaminergic neuron survival: mechanisms and therapeutic potential. Cell Death Dis. 2019. ↩︎ ↩︎
Cruz K, et al. Small molecule NTSR1 modulators for Parkinson's disease therapy. J Med Chem. 2023. ↩︎ ↩︎
Kim K, et al. The role of neurotensin in Alzheimer's disease pathophysiology. Mol Neurobiol. 2020. ↩︎
Chen X, et al. Neurotensin signaling in microglia mediates neuroinflammation and dopaminergic degeneration. Glia. 2021. ↩︎
Zhang Y, et al. Neurotensin modulates synaptic transmission in the substantia nigra. J Neurosci. 2021. ↩︎